Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Viridian Therapeutics (VRDN) to $44 from $42 and keeps an Outperform rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics initiated with a Buy at UBS
- Viridian Therapeutics: Advancing TED Pipeline, 2026 Catalysts, and New TSH Receptor Inhibitor Underpin Buy Rating
- Viridian Therapeutics: 2026 Clinical and Regulatory Catalysts, Strong Balance Sheet Support Buy Rating on VRDN
- Viridian Therapeutics: Building a Best-in-Class Thyroid Disease Franchise with Multiple Clinical Catalysts Supporting a Buy Rating
- Viridian Therapeutics: Multiple 2026 Catalysts and Pipeline Momentum Underpin Buy Rating